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The NCR receptors play a fundamental role in the cytotoxicity mediated by NK cells against tumor cells. In the current study, we
investigated possible HIV/AIDS-related changes in the expression of the NCR receptors comparing healthy donors, HIV/AIDS
patients, and HIV/AIDS patients with cancer (HIV/AIDSWC). The NCRs were quantified in NK cells (NKdim and NKbright) and
T lymphocytes from peripheral blood samples by flow cytometry. We found a significant decrease in the frequency of NK cells
expressing NKp46 in HIV/AIDS group (𝑝 = 0.0012). There was a decrease in the frequency of NK cells expressing NKp46 in the
HIV/AIDSWC group; however, this was not statistically significant. We found a significant decrease in the frequency of NK cells
expressing NKp30 in the HIV/AIDS group (𝑝 = 0.0144). There was a decrease in the frequency of NK cells expressing NKp30 and
in the HIV/AIDSWC group, but this was not statistically significant.There were no changes in the distribution of NK cells and their
subtypes in both groups.
1. Introduction
HIV-1 infection is characterized by a decline of CD4+
lymphocyte levels and systemic immune hyperactivation [1].
These factors, when associated, lead to exhaustion of immune
resources and an increased risk of cancer [2], such as Kaposi’s
sarcoma (KS) caused by human herpes virus 8 (HHV-8),
the non-Hodgkin lymphomas (NHL), some of which are
caused by Epstein-Barr virus, and cervical cancer caused
by oncogenic subtypes of human papillomavirus (HPV) [3].
These tumors are known as AIDS-defining cancers by the
Disease Control and Prevention Center (CDC) [4]. People
infectedwithHIV-1 also have an increased risk of a number of
non-AIDS-defining cancers [2, 4], including some associated
with coinfections or cigarette smoke [5, 6].
NK cells are a subset of lymphocytes that are capable of
eliminating malignantly transformed or infected cells. This
population of cells is primarily in peripheral blood and bone
marrow, although it can be found in secondary lymphoid
organs [7]. There are two distinct subtypes of NK cells based
on the density of the surface expression on CD56. Over
90% of NK cells belong to the CD56dim subtype, which has
as its main function cytotoxicity and is rich in granzyme
and perforin [7]. The second subtype, CD56bright, is rare in
the blood (±10%) and is responsible for the production of
cytokines [7].
The precise mechanisms through which NK cells rec-
ognize and eliminate malignant or virus infected cells are
complex and still not fully understood [8]. Unlike other
lymphocytes, NK cells do not have receptors for specific
antigens.Their cytolytic activity and cytokine production are
regulated through activation or inhibition of receptors on
their surface [7].These receptors compose distinct families of
proteins: lectin-like domains (CD94/NKG2A, HLA-E ligand
with inhibitory function andNKG2D, andMIC-A ligandwith
activating function), immunoglobulin-like domains (KIR),
and natural cytotoxicity receptors (NCR), where NCRs rep-
resent a family of characteristic NK cell markers [8].
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There are three types of NCR receptors: NKp46, Nkp44,
and NKp30. These receptors play a fundamental role in
the cytotoxicity mediated by NK cells against tumor cells,
whereas there is a close correlation between the expression
density of the NCR on NK cells and their ability to kill tumor
targets [9–11]. However, the ligands of these receptors in
tumor cells have not yet been identified [8].
Previous studies have observed changes in the NCRs in
HIV-1 infection [11–13]. These changes play a crucial role in
some neoplasmsmainly in cases of immunodepressionwhere
these receptors tend to be underexpressed [12, 14].
From a cancer perspective, prior studies observed
changes in expression of NCRs in patients withmalignancies,
which in part is explained in the tumor microenvironment
that is capable of overactive certain inflammatory responses
by secreting proinflammatory cytokines that allow increased
expression of these receptors [15, 16]. However, studies that
observe functional changes of the NK cells in patients with
both conditions are scarce.
The role of cancer in changing the profile of these cells
in HIV/AIDS or if the prevalence of cancer in these groups
is directly related to changes in these receptors given their
crucial role in the monitoring of malignant cells is still
uncertain.
The aim of this study was to evaluate the expression of
NCR receptors in the NK cells (and their subtypes) and to
compare HIV/AIDS patients and HIV/AIDS patients with
cancer (HIV/AIDSWC). This study offers new unexpected
viewpoints of the role of NK receptors and their possible
exploitation in a growing range of diseases, like cancer.
2. Methods
2.1. Study Design. Thiswas an observational study that used a
cross-sectional approach conducted from 2014 to 2015 at the
Department of Infectious and Parasitic Diseases of the Pedro
Ernesto University Hospital, Rio de Janeiro State University,
RJ, Brazil.
2.2. Study Subjects. The patients (groups HIV/AIDS and
HIV/AIDSWC) were recruited at the Department of Infec-
tious and Parasitic Diseases, Pedro Ernesto University Hos-
pital, Rio de Janeiro State University, RJ, Brazil. HIV-1
diagnosis was made through a standard screening enzyme-
linked immunosorbent assay (ELISA; Elecsys HIV combi
PT) and confirmed by Immunoblotting (Imunoblot Dual
Path Platform (DPP) HIV-1/2).
The inclusion criteria for the patient groups included
the following: confirmed diagnosis of HIV/AIDS formally
registered in medical records; age of 18 years or more; and
having started antiretroviral treatment (HAART); and for
the HIV/AIDSWC group they included confirmed diagnosis
of cancer registered formally in medical records and being
treated against cancer.
The exclusion criteria included the following: opportunist
infections within 6 months, diabetes, and autoimmune dis-
eases. To ensure that such conditions were not included in
the groups, an analysis of the medical records of all patients
captured for study was conducted. There were no exclusion
criteria from the point of view of the medicines used for the
treatment of HIV/AIDS and cancer.
The samples from the groups HIV/AIDS and HIV/
AIDSWCwere obtained from peripheral blood at theNucleic
Acids Laboratory of the Pedro Ernesto University Hospital,
RJ, Brazil.
Healthy donors were recruited at the Department of
Pathology and Laboratory, School of Medical Sciences, Rio
de Janeiro State University, RJ, Brazil. For the recruitment of
healthy donors, an interview was conducted, and when there
was no declaration of infections within 6months, cancer, dia-
betes, immunologic illness, or current use of immunomodu-
latory medications, blood samples were collected. A second
screening was performed based on laboratory examinations
and clinical records, and individuals presenting anomalies
and other conditions that could affect the immune system
were excluded.
All samples (5mLof peripheral blood)were collected into
a tube containing ethylenediamine tetraacetic acid (EDTA).
2.3. Ethics. This study was approved by the Ethics Committee
of the Hospital Universitário Pedro Ernesto/UERJ (CAAE
14189113.2.0000.5259). All samples were collected with writ-
ten informed consent.
2.4. Reagents. Anti-CD3-FITC clone UCHT1, anti-CD56-
PC5 clone N901, anti-CD335-PE (NKp46) clone BAB281,
anti-CD336-PE (NKp44) clone Z231, and anti-CD337-PE
(NKp30) clone Z25 were obtained from Beckman Coulter
(Fullerton, CA). The BDMultitest contained anti-CD3-FITC
(clone SK7), anti-CD8-PE (clone SK1), anti-CD45-PercP
(clone 2D1), and anti-CD4-APC (SK3) were obtained from
BD Biosciences (San Jose, CA).
Anti-CD335-PE, anti-CD336, and anti-CD337 were used
for the analysis of NCR family member expression. The BD
Multitest was used for the quantification of the T lymphocytes
CD4+ and CD8+. The anti-CD3-FITC and anti-CD56-PC5
were used for identification of the lymphocytes groups.
2.5. Flow Cytometry. The samples were stained with specific
monoclonal antibodies (5 𝜇L of each monoclonal antibody
was added to 100 𝜇L, approximately 1 × 106 leukocytes of
peripheral blood with EDTA) and incubated at room tem-
perature for 15min in the dark.The red blood cells were lysed
with a FACS Lyse reagent (BD Biosciences, San Jose, CA)
and centrifuged at 2000 rpm for 5min.The supernatants were
discarded, and the cells were washed twice with phosphate-
buffered saline (PBS) and resuspended in 200𝜇L of PBS. At
least 200,000 events were acquired using a FACScanto II flow
cytometer (BD Biosciences, San Jose, CA), and data were
analyzed using the FACS Diva (BD Biosciences, San Jose,
CA).
2.6. Gate Draw. Before gate draw, the dead cells and conju-
gates (doublets) were excluded from the analysis. For the gate
draw in the lymphocytes population, side scatter (SSC) and
forward scatter (FSC) were used. The antibodies anti-CD3
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Table 1: Baseline Characteristics from subjects in different groups.
Number of















Healthy donors 1/24 43 (20–65) NA NA NA NA NA
HIV/AIDS 5/20 45 (19–69) 4437 (419–9267) (<40–512.000) 0.71(0.11–1.57) Yes NA
HIV/AIDSWC 4/17 45 (30–69) 2628 (88–8679) (<40–113.000) 0.40(0.04–1.35) Yes
1800
(40–7488)
aThemedian (range) for each group is shown. bOnly the range for each group is shown. The HIV/AIDSWC group had eight patients with viral load classified
as “undetectable.”The HIV/AIDS group had eighteen patients with viral load classified as “undetectable.”These patients are not included in the table. NA: not
applicable.










NRTI + NNRTI + PI +
FI — 1
NRTI + NNRTI + PI 1 3
NRTI + NNRTI + II 2 —
NRTI + NNRTI 14 11
NRTI + PI 7 4
NRTI 1 2
NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-
nucleoside reverse transcriptase inhibitors; PI: protease inhibitor; FI: fusion
inhibitors; II: integrase inhibitors.
and anti-CD56 (present in all tubes) were used to separate
two cell populations: T cells (CD3+CD56−) and NK cells
(CD3−CD56+).TheNK cells were subdivided based onCD56
expression in two subsets: NK CD56dim and NK CD56bright.
Receptor expression of NCR was assessed separately for each
of these populations. Gates strategies were designed based on
Almeida-Oliveira et al. [7], as exemplified in Figure 1.
2.7. Statistical Analysis. Differences between groups were
analyzed using the Kruskal-Wallis nonparametric test (with
Student-Newman-Keuls posttest). Correlation analysis was
performed using Spearman’s test. Statistical analysis was
performed using BioStat version 5.0 software.
3. Results
3.1. Baseline Characteristics of Subjects. We studied 71 sub-
jects with ages ranging from 19 to 69 years. Our study
population was divided into three groups: healthy donors
(𝑛 = 25), HIV/AIDS patients (𝑛 = 25), and HIV/AIDS
patients with cancer (HIV/AIDSWC) (𝑛 = 21). The patients’
characteristics are shown in Table 1. The types of HAART are
shown in Table 2.
The types of cancer that composed the HIV/AIDSWC
group were Kaposi’s sarcoma (8) non-Hodgkin lymphoma
(8), anal carcinoma (1), fibrosarcoma (1), colon (1),mesenchy-
mal cells (1), and Hodgkin lymphoma (1). At the time of
collection, all patients were in treatment against the cancer.
3.2. Changes in Lymphocytes Populations. With flow cytome-
try, we defined the populations of interest based on CD3 and
CD56 expression (Figure 1). The percentage of classical T cell
population presented a slight increase in the HIV/AIDS and
HIV/AIDSWC groups; however, no statistical difference was
observed among the different groups nor in absolute number
(Table 3). No differences were observed in the percentage of
the total lymphocyte population among the different groups
(Table 3).
The percentage of CD4+ and CD8+ subpopulations was
affected by HIV/AIDS, as expected (Table 3). The groups
HIV/AIDS and HIV/AIDSWC showed a decrease of the
CD4+ percentage when compared with the healthy group
(𝑝 < 0.0001). The same was found in absolute number
(𝑝 = 0.0002). The HIV/AIDS and HIV/AIDSWC groups
also showed a significant statistical difference in the CD4+
percentage between themselves (𝑝 < 0.05). This difference
was also observed in absolute number (𝑝 < 0.05).
The HIV/AIDS and HIV/AIDSWC groups showed an
increase of the CD8+ percentage when compared with the
healthy group (𝑝 < 0.0001). The same was found in absolute
number (𝑝 = 0.0007).
No differences were observed in the percentage of the NK
cell population among different groups (Table 3).
The HIV/AIDS and HIV/AIDSWC groups did not show
statistical differences in the WBC count when compared to
the healthy group (Table 3).
3.3. Changes in NK Cells Subsets. No differences were
observed in the percentage of the CD56dim cell population
among different groups (Table 3). In addition, no differences
were observed in the percentage of the CD56bright cell
population among different groups (Table 3).
3.4. Changes in NCR Receptors. We investigated the expres-
sion of three receptors belonging to the NCR family: NKp44,
NKp46, and NKp30. None of these receptors were expressed
at considerable levels in T cells. In our study, the expression
of NKp44 in the studied cells is not apparent in considerable
levels.


























































































































Figure 1: Gate strategy based on example of analysis of a healthy donor (male, age 31 years). Gate strategy: (a) lymphocyte population based on
FCS and SSC. (b) Identification of cells populations based on CD3 and CD56 expression, T cells (CD3+CD56−), and NK cells (CD3−CD56+).
(c) Identification of NK cell subsets based on CD56 expression. (a–c) the frequency of each cell population is represented in percentage
inside each graphic. (d–f) NKp46 expression in each of these cells populations, for example, in NK cells (d), NK CD56dim subset (e), and NK
CD56bright subset (f). (d–f) the frequency of NKp46 cells in each cell population is represented in percentage inside each graphic.
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Table 3: Frequency of T and NK (CD56dim and CD56bright) cells from subjects in different groups.
Median Mean ± SD 𝑝 value
(Kruskal-Wallis test)Healthy HIV/AIDS HIV/AIDSWC Healthy HIV/AIDS HIV/AIDSWC
Percentage (%)
Total
lymphocytes 35.50 35.50 30.00 33.61 ± 9.09 35.44 ± 10.44 32.39 ± 11.94 0.3617
T cells 55.20 59.40 57.70 54.48 ± 11.54 60.70 ± 9.14 57.52 ± 11.28 0.2204
CD4 T cells 53.00 38.20a 23.60ab 54.44 ± 11.12 37.91 ± 10.74 26.28 ± 14.99 <0.0001
CD8 T cells 36.10 53.00a 62.00a 35.26 ± 9.96 53.12 ± 10.32 60.66 ± 15.45 <0.0001
NK cells 11.30 9.70 11.60 13.21 ± 6.69 11.15 ± 7.08 12.93 ± 6.75 0.4699
CD56dim NK
subset 96.50 95.70 94.80 95.72 ± 2.94 94.23 ± 5.10 93.70 ± 5.14 0.2499
CD56bright NK




WBC count 7000 5500 6800 7148.00 ± 2233.85 5924.00 ± 1860.17 7261.90 ± 2789.52 0.0722
Total
lymphocytes 2280 1960 2110 2256.40 ± 566.09 2007.60 ± 597.02 2341.42 ± 1152.39 0.4601
T cells 1159 1198 1314 1214.16 ± 416.83 1229.88 ± 454.55 1329.95 ± 640.95 0.8751
CD4 T cells 655 453a 280ab 665.36 ± 272.59 472.56 ± 228.92 355.42 ± 303.63 0.0002
CD8 T cells 369 603a 753a 430.08 ± 209.90 645.84 ± 252.61 812.38 ± 437.61 0.0007
NK cells 274 194 248 292.20 ± 173.04 211.76 ± 131.60 310.28 ± 235.15 0.1501
CD56dim NK
subset 257 185 239 281.60 ± 172.52 203.32 ± 131.54 294.76 ± 226.17 0.1817
CD56bright NK
subset 9 7 10 10.92 ± 7.29 7.72 ± 4.92 15.23 ± 12.39 0.1137
Percentage values represent the frequency (in percentage and absolute numbers) in median of T cells, CD4+ T cells, CD8+ T cells, and NK cells among all
peripheral blood lymphocytes and the frequency of CD56dim and CD56bright NK cells among the NK cell population. Means and standard deviations (SD)
are also shown. Significant 𝑝 values are highlighted in boldface type. a = statistical difference to the healthy group (𝑝 < 0.05); b = statistical difference to the
HIV/AIDS group (𝑝 < 0.05). Statistical comparisons made by Kruskal-Wallis (with Student-Newman-Keuls posttest).
We found a significant decrease in the percentage of the
frequency of NK cells expressing NKp46 in the HIV/AIDS
group (𝑝 = 0.0012). This difference was also observed in
absolute number (𝑝 = 0.0018). There was a decrease in
percentage and absolute number of the frequency of NK cells
expressing NKp46 in the HIV/AIDSWC group; however, it
was not statistically significant (Table 4). We also found a
significant decrease in the percentage of the frequency of
CD56dim cells expressing NKp46 in the HIV/AIDS group
(𝑝 = 0.0008). This difference was also observed in absolute
number (𝑝 = 0.0019). The HIV/AIDS and HIV/AIDSWC
groups also showed a statistical difference in the frequency of
NK cells and CD56dim cells expressing NKp46 in percentage
between themselves (𝑝 < 0.05). This difference was also
observed in absolute number (𝑝 < 0.05).
A significant decrease in percentage of the frequency of
NK cells expressing NKp30 in the HIV/AIDS group (𝑝 =
0.0144) was observed. This difference was also observed in
absolute number (𝑝 = 0.0011). There was a decrease in
percentage and absolute number of the frequency of NK
cells expressingNKp30 in theHIV/AIDSWCgroup; however,
these results were not statistically significant (Table 4). We
also found a significant decrease in percentage of the fre-
quency of CD56dim cells expressing NKp30 in the HIV/AIDS
group (𝑝 = 0.0286). This difference was also observed
in absolute number (𝑝 = 0.0022). The HIV/AIDS and
HIV/AIDSWC groups also showed a statistically significant
decrease in the frequency of NK cells and CD56dim cells
expressing NKp30 in absolute number between themselves
(𝑝 < 0.05).There was also a significant increase in expression
of NKp30 in CD56bright cells in the HIV/AIDSWC group
(𝑝 = 0.0275) in their absolute number. This difference was
not observed in percentage (Table 4). The HIV/AIDS and
HIV/AIDSWC groups also showed a significant difference
in the frequency of CD56bright cells expressing NKp30 in
absolute number between themselves (𝑝 < 0.05).
3.5. Correlation Analysis. Correlation analysis detected a
positive correlation between the expression of NKp46 and
NKp30 in total NK cells (𝑝 < 0.0001, rs = 0.9046) and their
subtypes CD56dim (𝑝 < 0.0001, rs = 0.9297) in theHIV/AIDS
group.
A positive correlation was detected between the expres-
sion of NKp46 and NKp30 in total NK cells (𝑝 < 0.0001,
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Table 4: Frequency of T and NK (CD56dim and CD56bright) cells expressing NCRs receptors in different groups.
Median Mean ± SD p value
(Kruskal-Wallis test)Healthy HIV/AIDS HIV/AIDSWC Healthy HIV/AIDS HIV/AIDSWC
Percentage (%) of
NKp46
NK cells 72.00 50.40a 69.50b 70.68 ± 22.38 48.03 ± 19.10 61.78 ± 21.24 0.0012
CD56dim NK subset 72.50 43.00a 59.60b 70.13 ± 22.80 45.38 ± 19.75 59.69 ± 22.13 0.0008
CD56bright NK subset 93.90 92.50 95.10 93.28 ± 5.19 92.54 ± 6.27 93.26 ± 6.51 0.7706
Percentage (%) of
NKp30
NK cells 38.00 20.50a 33.10 38.79 ± 17.33 24.90 ± 13.99 31.66 ± 16.25 0.0144
CD56dim NK subset 41.00 21.30a 32.20 39.27 ± 15.96 26.64 ± 14.81 32.21 ± 17.22 0.0286
CD56bright NK subset 11.80 10.30 14.40 11.44 ± 6.63 16.06 ± 14.49 15.60 ± 7.82 0.2068
Absolute numbers of
NKp46 (cells/mm3)
NK cells 158 90a 136b 199.04 ± 132.32 99.68 ± 74.37 167.23 ± 109.45 0.0018
CD56dim NK subset 145 79a 127b 190.16 ± 131.71 91.04 ± 71.58 154.14 ± 106.78 0.0019
CD56bright NK subset 8 7 10 10.24 ± 6.78 7.08 ± 4.34 14.09 ± 11.07 0.0754
Absolute numbers of
NKp30 (cells/mm3)
NK cells 86 38a 72b 111.68 ± 87.80 49.32 ± 41.16 80.09 ± 50.97 0.0011
CD56dim NK subset 83 42a 69b 108.44 ± 83.95 49.52 ± 39.82 75.76 ± 48.23 0.0022
CD56bright NK subset 1 1 2b 1.32 ± 1.31 1.04 ± 1.30 2.42 ± 2.20 0.0275
The values shown represent the percentage and absolute number in median within each cell population expressing a given receptor NCR. Means and standard
deviations (SD) are also shown. Significant 𝑝 values are highlighted in bold. a = statistical difference to the healthy group (𝑝 < 0.05); b = statistical difference
to the HIV/AIDS group (𝑝 < 0.05). Statistical comparisons were made by Kruskal-Wallis (with Student-Newman-Keuls posttest).
rs = 0.7580) and their subtypes CD56dim (𝑝 = 0.0003, rs
= 0.7156) and CD56bright (𝑝 < 0.0001, rs = 0.8096) in the
HIV/AIDSWC group.
A positive correlation was detected between the expres-
sion of NKp46 and NKp30 in total NK cells (𝑝 < 0.0001,
rs = 0.7272) and their subtypes CD56dim (𝑝 < 0.0001, rs
= 0.7838) and CD56bright (𝑝 < 0.0001, rs = 0.7121) in the
healthy donor group. A positive correlation was also detected
between CD4+ T cells and the expression of NKp46 (𝑝 =
0.0008, rs = 0.6241) and NKp30 (𝑝 = 0.0009, rs = 0.6232)
in CD56bright cells.
There was no correlation between the expression of NCR
receptors (NKp46 and NKp30) and CD4 T cell count or
CD4/CD8 ratio and infection duration in any of the patients
groups studied (Table 5).
4. Discussion
4.1. Distribution of the Lymphocyte Subsets (NK and T Lym-
phocytes). The hallmark of HIV-1 infection is the selective
depletion of the CD4+ T cell caused by HIV-1 tropism
by this population of cells, due to the high affinity of the
protein of the viral envelope through the CD4 receptor [17]
and the depletion due to permanent immune activation by
inflammatory cytokines in the chronic phase of infection [18].
This is reflected in the values presented in our study,where the
HIV/AIDS and HIV/AIDSWC groups differed significantly
in percentage and absolute values in comparison to the
healthy group (𝑝 < 0.0001 and 𝑝 = 0.0002, resp.). However,
according to Horberg et al. [19], treatment with HAART
increased the CD4+ count in patients with HIV/AIDS; this
was not reflected in our study. In contrast, the proportion
of CD8+ T cells increased after HIV/AIDS infection in both
groups in percentage and absolute number in comparison to
the healthy group (𝑝 < 0.0001 and 𝑝 = 0.0007, resp.). This
increase is resonant with the findings of Naranbhai et al. [20]
when studying the lymphocyte expansion in HIV-1 patients.
It is important to mention that the use of certain HAART can
directly affect the distribution of these cells, as demonstrated
in the study of Hunt et al. [21], where the use of a drug called
Maraviroc did not affect the cell recovery rate of CD4+ T
cells but increased CD8+ T cells counts in peripheral blood.
The percentage and absolute values of the distribution of
NK cells found by our study in the lymphocyte segment were
compatible with the study by Alter et al. [22]. These authors
observed no significant differences in all NK cells, including
subsets (CD56dim and CD56bright). In this same study, the
total percentage of NK cells observed in patients with acute
infection proved to be significantly increased. However, in
our study, the majority of individuals in the chronic stage
of HIV/AIDS were studied. Together, these data suggest that
the population of NK cells is usually expanded during acute
infection, returning to similar levels of those observed in
noninfected individuals [20, 22].
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Table 5: Correlation analysis between NCRs and CD4 T cells, CD4/CD8 ratio, and days since HIV/AIDS diagnosis.
NKp30 CD4 T cells CD4/CD8 ratio Days since HIV/AIDS diagnosis
NK cells
Healthy donors
NKp46 0.7272 (p < 0.0001) 0.2585 (𝑝 = 0.2121) −0.1408 (𝑝 = 0.5019) NA
NKp30 — 0.1617 (𝑝 = 0.4400) −0.0004 (𝑝 = 0.9985) NA
HIV/AIDS group
NKp46 0.9046 (p < 0.0001) 0.2400 (𝑝 = 0.2477) 0.1928 (𝑝 = 0.3559) 0.0677 (𝑝 = 0.7478)
NKp30 — 0.2821 (𝑝 = 0.1718) 0.3249 (𝑝 = 0.1130) 0.1428 (𝑝 = 0.4960)
HIV/AIDSWC group
NKp46 0.7580 (p < 0.0001) 0.3351 (𝑝 = 0.1375) 0.0754 (𝑝 = 0.7454) 0.0948 (𝑝 = 0.6827)
NKp30 — 0.3677 (𝑝 = 0.1010) 0.2671 (𝑝 = 0.2417) 0.3910 (𝑝 = 0.0795)
CD56dim NK subset
Healthy donors
NKp46 0.7838 (p < 0.0001) 0.2220 (𝑝 = 0.2861) −0.1461 (𝑝 = 0.4859) NA
NKp30 — 0.2208 (𝑝 = 0.2889) 0.0192 (𝑝 = 0.9273) NA
HIV/AIDS group
NKp46 0.9297 (p < 0.0001) 0.2213 (𝑝 = 0.2877) 0.1986 (𝑝 = 0.3412) 0.0962 (𝑝 = 0.6473)
NKp30 — 0.3037 (𝑝 = 0.1399) 0.3446 (𝑝 = 0.0916) 0.1946 (𝑝 = 0.3512)
HIV/AIDSWC group
NKp46 0.7156 (p = 0.0003) 0.3558 (𝑝 = 0.1133) 0.0864 (𝑝 = 0.7095) 0.1039 (𝑝 = 0.6540)
NKp30 — 0.3571 (𝑝 = 0.1119) 0.3112 (𝑝 = 0.1696) 0.4727 (𝑝 = 0.0504)
CD56bright NK subset
Healthy donors
NKp46 0.7121 (p < 0.0001) 0.6241 (p = 0.0008) 0.0698 (𝑝 = 0.7402) NA
NKp30 — 0.6232 (p = 0.0009) 0.2029 (𝑝 = 0.3307) NA
HIV/AIDS group
NKp46 0.3303 (𝑝 = 0.1068) 0.3947 (𝑝 = 0.0508) 0.0571 (𝑝 = 0.7863) 0.2101 (𝑝 = 0.3135)
NKp30 — 0.0987 (𝑝 = 0.6386) 0.1911 (𝑝 = 0.3600) 0.3172 (𝑝 = 0.1222)
HIV/AIDSWC group
NKp46 0.8096 (p < 0.0001) 0.3094 (𝑝 = 0.1722) −0.0091 (𝑝 = 0.9687) −0.1055 (𝑝 = 0.6489)
NKp30 — 0.2354 (𝑝 = 0.3043) 0.0524 (𝑝 = 0.8215) 0.0975 (𝑝 = 0.6743)
The numbers are shown as “rs (p)”. 𝑝 < 0.05. Significant p values are highlighted in bold. The correlation coefficient rs > 0 shows positive correlation; rs < 0
stands for negative correlation. 𝑝 < 0.05 and rs > 0.4 indicates the significant correlation between the two indexes. NA: not applicable.
Since the advent of HAART, researchers have shown
different degrees of recovery distribution in lymphocyte
subpopulations, which may explain the lack of significant
differences in the distribution ofNK cells (and their subtypes)
[23, 24] as well as lymphocyte T cells [19]. In contrast,
Tarazona et al. [25] found a selective reduction of the
subtype CD56dim and preservation of the subtype CD56bright.
Other authors also observed reduction in the distribution
of NK cells [26–28]. This reduction appears to be partially
attributable to the emergence of a novel subset of NK
cells that is rare in healthy individuals, CD3−CD56−CD16+
NK cells that were described during chronic infections by
HIV/AIDS [29]. These cells express a similar receptor profile
for CD56dim NK cells but are relatively cytotoxic and do not
secrete cytokines. Due to the lack of appropriatemarkers, this
subpopulation cannot be tested in our study.
4.2. Expression of CD336 (NKp44). TheNKp44 expression is
only induced in activated NK cells and has been shown to
be overexpressed in HIV+ patients with low levels of CD4+
T cells [13]. In our study, the expression of NKp44 in the
studied cells does not show considerable levels (data not
shown). More thorough ex vivo studies may assess if there are
abnormalities in the expression of this receptor in these cells.
However, Vieillard et al. [13] and Fausther-Bovendo et al. [30]
observed an increase in NKp44 expression in HIV+ patients.
In contrast, DeMaria et al. [12] andMarras et al. [31] observed
a decrease of the NKp44 functioning in HIV-1 infection and
making the analysis divergent.
There is evidence that suggests that NK cells may be
involved in the depletion of CD4+ T cells. It is known that,
after infection by HIV-1, a significant fraction of CD4+ T cell
subset expresses NKp44L, an activation ligand of the NKp44
receptor that is induced by a HIV gp41 peptide [13]. The
NKp44L expression makes CD4+ T cells sensitive to lysis by
NK cells process. This expression is strongly correlated with
the decline in CD4+ cell count and increase of viral load [13].
The NKp44L function in the depletion of CD4+ T cells was
confirmed in a study by Vieillard et al. [32]. Ward et al. [33]
suggest that HIV-1 has acquired the ability to use NK cells
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to disarm the host immune system, triggering the selective
killing of uninfected CD4+ T cells.
The activation of NKp44 can be induced by tumor cells
[32]. Some studies showed that NKp44 and other NCRs
usually have an important role in the lysis mediated by NK
cells in various tumors, including carcinomas, melanomas,
neuroblastomas, myeloid and lymphoblastic leukemia, mul-
tiple myeloma, and B cells transformed by the Epstein-Barr
virus [34].
4.3. Decreased Expression of CD335 (NKp46) and CD337
(NKp30). NKp46 is expressed by NK cells that are either
activated or deactivated by sending activating intracellular
signals by association with the CD3𝜁 chain or the 𝛾 chain
Fc𝜀RI receptor [35]. Thus, these receptors, in combination
with the NKG2D, are seen as being responsible for the
spontaneous cytotoxic activity of NK cells in humans against
many diseases (e.g., melanomas, carcinomas, and B lym-
phocytes infected by the Epstein-Barr virus). In general, the
level of NKp46 expression is directly correlated with the
degree of cytotoxicity of NK cells [36]. The receptor NKp30
is selectively expressed on NK cells and is associated with
the dendritic cells. Human dendritic cells express the ligand
for NKp30, but this ligand is unknown until now [37]. This
ligand also mediates the NK-DC interaction resulting in
the activation of DC or their death limiting the supply of
dendritic cells [37].
Our study found a decreased frequency of NKp46 (𝑝 =
0.0012) and NKp30 (𝑝 = 0.0144) in NK cells in the
HIV/AIDS group. Previous studies have also sought to assess
the overall expression of NCR receptors in HIV+, showing
that HIV-1 leads to an overall decrease of NCRs [11–13].
According to De Maria et al. [12], there was a significant
decrease in expression of NKp46 and NKp30 receptors on
NK cells in HIV+ patients. The study of Frias et al. [11] also
supports this analysis, when there was a lower expression of
NKp46 and NKp30 receptors in NK cells of HIV+ patients.
HIV-1 also induces functional changes in the activation
of NK cells [12, 14]. For example, the activation with the
K562 cell line was shown to reduce expression of CD16 and
suppress the ability of NK cells to respond to additional
stimulation [38]. These data suggest that NK cells in HIV-
1 patients, in vitro, have a considerable decrease in NCR
activation, which is consistent with a decrease in expression
of NKp46 and NKp30 molecules observed in NK cells in
peripheral blood.The reduced expression of NCR in NK cells
found in our study could be responsible, at least partially, for
decreased lytic activity against the virus or tumor cells. These
results suggest that modulation of receptor expression on NK
cells may play a role in the pathogenesis of HIV-1 and provide
new insights into immunologic alterations in advanced stages
of the disease [35].
Our study found a partial recovery in the expression of
NKp46 andNKp30 receptor inNK cells in theHIV/AIDSWC
group, which, despite being lower than in the group of healthy
donors, was not statistically significant. It is known that the
release of cytokines in the tumor microenvironment can
induce the expression of these receptors. Different cells can
participate in this modulation, such as Th17. Studies show
that these cells can directly mediate the antitumor response
through the effector cell recruitment to the tumormicroenvi-
ronment [15, 16]. One way is through IL-17 produced by these
cells which acts synergistically with the IFN inducing the
production of chemokines CXCL10 andCXCL9 bymalignant
cells and macrophages, which induces the cell traffic that
conducts antitumor functions [39]. Moreover, the ability of
NK cells is increased in the presence of IL-17, since this
increases cytokine expression of cytotoxic molecules such
as TNF, IFN-𝛾, perforins, and granzymes B and NK cell
activation receptors (NKp46, NKp44, NTB-A, and NKG2D)
[40].
Another possibility for our results is the fact that the
most common malignancies in the HIV/AIDSWC group
induce the production of IL-12. Previous studies developed
in cell culture have demonstrated that IL-12 has induced
the expression of these receptors [41, 42]. It is known
that the production of cytokines such as IL-15 and IL-
18 have similar effects and may also act in the activation
and subsequent expression of NKp46 [43, 44]. The various
cancers and oncoviruses associated with HIV-1 (which is a
majority of the tumormanifestations found in our groupwith
HIV/AIDSWC) are capable of overactivating such inflam-
matory responses by the secretion of these proinflammatory
cytokines and chemotaxis and extravasation of lymphocytes
by the site of infection [45, 46].
Our data suggest that although the cancer and its asso-
ciated inflammatory processes stimulate the expression of
NKp30 and NKp46 in NK cells in chronic conditions of
HIV/AIDS, this expression leads to a less severe manner,
keeping these receptors expressed at a subnormal level but
higher than the HIV/AIDS patients without cancer. These
preliminary findings increase the interest in the role of NK
cells and its receptors in conducting a cancer process and
the history of infection, considering that the expressions of
NCRs decrease along the progression of the disease [12]. It is
possible that during this HIV/AIDS progression the increase
in these NCRs represents an immunological indicative of
cancer and other systemic inflammatory conditions.
In addition, the NCR expression in cancer patients at
normal or subnormal levels can be crucial to the survival
rates of the patient, because it is known that the expression of
these receptors is also associated with a good prognosis [47].
Our study design did not allow us to analyze the prognosis of
these patients. In this respect, we suggest other longitudinal
studies to better understand the differences in the distribution
of these receptors and allow monitoring of these changes
over a longer period in order to relate changes in NCRs with
the incidence of cancers or prognosis of cancer group to
relate it to the expressions of NCRs. Many aspects need to
be clarified in future studies. For example, measurements of
inflammatory markers and immune activation of NK cells
need to bemade to actually establish a factual influence of the
tumor microenvironment and to determine the implications
of such systemic exposure in NK cells with the significant
increase of the NCRs in the HIV/AIDSWC group when
compared to the HIV/AIDS group.
Regarding the influence of HAART use in the expression
of receptors, Michaëlsson et al. [47] analyzed the frequency
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of NKp30+ and NKp46+ cells in patients with and without
treatment. Although the monitoring was only one year, they
found no clear differences between the patients who had been
treated and those who had not. Frias et al. [11] also did not
obtain a direct relationship between the use of HAART and
the recovery of these receptors. However, the same study
noted that the period with an undetectable viral load was
related to increased recovery of NKp30 and NKp46. This
finding suggests that although long-term use of HAART
does not induce a direct recovery of NCRs, more prolonged
use may lead to the restoration of the innate immunity
and consequently viral suppression, and in the long-term in
patients older than 85months at load, an “undetectable” could
result in improved expression of NCRs, even at levels below
that of healthy people. However, none of the patients in our
study had an extended period of viral suppression in order to
provide such recovery.
Through our correlation analysis, it was possible to
observe an association between NKp46 and NKp30 receptors
in all groups. These results were expected from previous
studies including De Maria et al. [12], Wong et al. [35],
and Lu et al. [40], since both receptors are constitutive NK
cells, and expression levels of these receptors are subject to
the similar variables and condition esplanades in our study.
The only exception was in CD56bright cells in HIV/AIDS
patients without cancer that were not correlated (rs = 0.3303,
𝑝 = 0.10680). It is possible that there are repercus-
sions of HIV/AIDS in CD56bright, and these are poorly
known.
Regarding the influence of other parameters in the
expression of these receptors, our analysis allowed us to
establish any correlation between these and the CD4 T cell
numbers, CD4/CD8 ratio, and days of infection. These data
are consistent with the findings of Frias et al. [11], which did
not observe influence of these variables in the expression of
NCRs.
Regarding the relationship observed between NKp46 (rs
= 0.6241, 𝑝 = 0.0008) and NKp30 (rs = 0.6232, 𝑝 = 0.0009)
receptors and CD4+ T cells in CD56bright cells in healthy
donors, it is possible that there are mechanisms of interaction
betweenNKbright cells andCD4+ T cells thatmay be related to
expression of NCRs [48]. However, the forms of interaction
between these cells are still poorly known, particularly the
repercussions of these interactions in HIV/AIDS.
Finally, we hope that this study may contribute to
understanding natural cytotoxicity receptors in patients with
HIV/AIDS and cancer. It is crucial to consider that changes in
NCRs may result in the history of the diseases as well as loss
of efficiency in the monitoring of cancer cells by NK cells that
together with the immunosuppression context of HIV/AIDS
are critical in the beginning and throughout the evolution of
these neoplastic diseases. We emphasize the need to study
other types of receptors on NK cells such as lectin and KIR
in patients with cancer and chronic HIV/AIDS to bring more
depth to the subject.
4.4. Study Limitations. The technical limitations of this
study include a lack of auxiliary markers to observe the
CD56−CD16+ population (NK CD56neg) and the impossibil-
ity of activation ofNK cells ex vivo (NKp44+) to assess if there
are abnormalities in the expression of this receptor in these
cells.
We cannot correlate the decreased expression of the
NCRs with the function of the NK cell. A FACS-based
cytotoxicity assay or cytokine production assessment would
be extremely helpful to establish the functional consequences
of NCR downmodulation.
The limitations of this study include a small sample size,
a single-centered hospital-based study, and the impossibility
of stratification to sex, age, cancer type, and treatment
(HIV/AIDS as well as cancer).
5. Conclusion
There were no changes in the distribution of NK cells and
their subtypes in either of the groups.Decreased expression of
receptors NKp46 and NKp30 was observed in the HIV/AIDS
group. The expression of NCR in NK cells in patients with
HIV/AIDS and cancer was shown to be higher in HIV/AIDS
patients without cancer.
More studies are needed that consider larger study groups
and include the possibility of stratifying results to see if these
findings are persistent in groups of different genders and
treatments and, in the case of cancer patients, their cancers.
It is necessary to determine if the changing balance of NK
receptor expression may influence susceptibility to various
diseases such as infections and cancer.
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